| Project/Area Number |
22591079
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATOH Masataka 福島県立医科大学, 医学部, 講師 (30404875)
尾山 徳孝 福島県立医科大学, 医学部, 講師 (30332927)
川上 佳夫 福島県立医科大学, 医学部, 講師 (80381367)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 膠原病 / 強皮症 / 皮膚硬化 / 線維化 / 抗線維化 / ブレオマイシン / 治療 |
|---|
| Research Abstract |
In this project, we examined the anti-fibrotic effects of sunitinib and bosentan in bleomycin-induced murine scleroderma model. Sunitinib (4mg/kg/day, 40 mg/kg/day) was orally administered 5 times per week for 3 weeks, along with local bleomycin treatment. Dermal sclerosis was significantly reduced, as well as dermal thickness, mast cell number, and collagen contents in the skin. By contrast, lung fibrosis was not suppressed, suggesting difference of susceptibility of bleomycin between lung and skin. In another experiment, oral bosentan (150μg/ml) was applied along with bleomycin treatment.Oral bosentan inhibited dermal sclerosis and follicular atrophy caused by bleomycin injection,infiltration and degranulation of mast cells in lesional skin. Also, oral bosentan inhibited migration of α-SMA-positive myofibroblasts with increase of E-selectin-negative vasculature in bleomycin-injected skin. Those new medicines are expected to be favorable for the treatment of human scleroderma.
|
